The Angel® Catheter has received CE Mark approval and is commercially available
in countries recognizing the CE Mark.
In the United States, the Angel® Catheter is classified as an investigational device.
Limited by Federal or United States law to investigational use.
BiO2 Medical has created the Angel® Catheter to protect critically ill patients from acute Pulmonary Embolism (PE). The innovative design incorporates a retrievable Inferior Vena Cava (IVC) filter, permanently attached to a triple lumen central venous catheter. Placed at the patient’s bedside, the Angel® Catheter is intended to provide protection from PE, immediately following admission, while simultaneously allowing for central venous access in critically ill patients. For information on cases with the Angel® Catheter please watch the 2013 ICS ‘State of the Art’ Meeting Optimising Pulmonary Embolism Prevention: Clinical Experience with the Angel® Catheter Symposium video.
The current objective for BiO2 Medical is to investigate, manufacture, and commercialize the Angel® Catheter; to provide prophylactic Pulmonary Embolism protection and access to the central venous system in critically ill patients. Pictured here is Mrs. Doreen Carter, the first patient to receive BiO2 Medical’s Angel® Catheter in the European Union at Royal Berkshire Hospital, in Reading, UK. Dr. Carl Waldmann, Consultant Anaesthetist & Intensive Care, Royal Berkshire NHS Trust, was quoted on BBC Radio as saying, “the new device can have a dramatic impact on most patients in intensive care who cannot be given anti-blood clotting medications.”Read More!
BiO2 Medical, Inc. was founded in December of 2006, by Luis F. Angel, MD, Christopher E. Banas, and Paul Castella, PhD. The company was formed to design, develop, and subsequently manufacture a range of novel medical devices, in response to unmet clinical needs.
The current objective for BiO2 Medical is to investigate, manufacture, and commercialize the Angel® Catheter; an innovative medical device designed to provide prophylactic Pulmonary Embolism protection and access to the central venous system in critically ill patients.
BiO2 Medical has corporate headquarters in San Antonio, Texas, and a research and development (R&D) and manufacturing facility in Golden, Colorado. The Golden, Colorado facility is certified per ISO 13485:2003 and includes a state of the art 1,000 ft.2 clean room certified as a class 8 (100,000) controlled environment (CER).